Prosight Management Invests $10.27 Million in Nektar Therapeutics Ahead of Key Phase 3 Launch
On May 15, 2026, Prosight Management disclosed a purchase of 180,367 shares of Nektar Therapeutics (NKTR), valued at approximately $10.27 million based on quarterly average pricing. The investment increased the firm's stake in NKTR by nearly $29.43 million when including share price appreciation.
Tickers: $NKTR
Topics: biopharmaceuticals investment SEC filing